DNA Vaccine Market Size, Share, and Industry Analysis By Type (Prophylactic and Therapeutic), By Indication (COVID-19, Cancer, and Others), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others), and Regional Forecast till 2032

The global DNA vaccine market is growing considerably due to the growing demand for innovative vaccine technologies and growing infections of the infectious diseases. The benefits of DNA vaccines include the stability at room temperature and the induction of two forms of immune response. Based on statistics available at the U.S. Food and Drug Administration, the U.S. currently has five FDA-approved DNA vaccines and 57 National Institutes of Health (NIH)-funded research programs are currently involved in the development of such vaccines, pointing to substantial state-sponsored R&D initiatives. Increased investment in biotechnology is another factor behind the market, with 12 facilities to produce DNA vaccines having been reported by the U.S. department of energy.

DNA Vaccine Market Driver

Genetic Engineering Advances Propel DNA Vaccine Development

Genetic engineering innovations on DNA vaccines are being driven by technologies. According to the statistics on ClinicalTrials.gov, 42 active DNA vaccine clinical trials in the U.S. demonstrate strong research activity. The increasing rate of illnesses like COVID-19 and cancer is another source of demand. The U.S. National Cancer Institute indicates 3,400 patients are enrolled in cancer treatments using DNA vaccines. Moreover, the U.S. Patent and Trademark Office indicated that 84 patent application documents pertaining to a DNA vaccine are annually submitted, meaning that the industry is rather high-innovation.

DNA Vaccine Market Restraint

Stringent Regulatory Approvals Limit DNA Vaccine Commercialization

Restrictive regulatory policies are a threat to DNA vaccine commercialization. It means that there are only three DNA vaccines approved in the EU (according to the European Medicines Agency), and it is a testament to the strict approval criteria. The costs involved in development are also very high to support the market growth and in the EU 66 patent applications have been filed every year, according to the European Patent Office. It also has patterned high value but expensive products such that the export of DNA vaccine amounts to 720 million per annum, according to the U.S. Trade Representative. These can slow down the market growth especially in resource-constrained areas.

DNA Vaccine Market Opportunity

Emerging Economies Unlock New Growth Opportunities for DNA Vaccines

DNA vaccines have great growth potentials in emerging economies. According to the Indian Council of medical research, there are 38 registered clinical trials in India with a growing research emphasis. Veterinary uses also carry possibility with the prevention of livestock diseases being of note. U.K. Research and Innovation stated that there are 48 government grants worth 48 million pounds helping in the development of DNA vaccines, which gives a clear picture of how interested the public sector is into it. Moreover, according to the information provided by China National Medical Products Administration, there are 41 DNA vaccine development laboratories in China, which shows the potential of promising development in the region.

Segmentation

Key Insights

The report covers the following key insights:

• Key Industry Trends
• Number of Patent Filings
• Investments in Research
• Key Industry Developments

Analysis By Type

By Type, the DNA Vaccine Market is divided into Prophylactic, Therapeutic. 

The prophylactic segment will be the largest as it will utilize projects in preventing diseases like COVID-19 and HPV. The therapeutic segment also has been predicted to expand enormously as a result of its application prospects in the treatment of cancer.

Analysis By Indication

By Indication, the DNA Vaccine Market is divided into COVID-19, Cancer & Others. 

The COVID-19 segment is at the forefront presently due to the hyped demand of vaccines around the globe. Nonetheless, it is projected that the cancer segment will record a significant growth, due to the continuing research and clinical trials.

Analysis By Distribution Channel

By Distribution Channel, the DNA Vaccine Market is divided into Hospital & Retail Pharmacies, Government Suppliers & Others. 

According to the data of the United States Department of Energy, 12 facilities are available in the United States, producing DNA vaccines (suppliers of government).

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on geography, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America is the dominant market of DNA vaccine in the world, with the highest number of research, development, and commercialization of the vaccine. The U.S. National Institutes of Health has 57 ongoing NIH-funded studies on DNA vaccine development nationwide, according to the available statistics. There is also a high intellectual property development around 84 patents per year related to DNA vaccines by the U.S Patent and Trademark Office. There is a large market activity with exports of the DNA vaccine amounting to $720 million annually as reported by U.S. Trade Representative. The level of patient engagement is also impressive, and the National Cancer Institute estimated 3.4 thousand patients participating in DNA vaccine clinical trials. The fully developed environment of research facilities, manufacturing capacity, and regulatory assistance in this region entrenches North America as the leader in the DNA vaccine market.

Europe has a major presence in DNA vaccine market with cooperative supportive research, and the presence of the regulatory environment. Three DNA vaccines have now been approved in the EU with the European Medicines Agency being ahead in its progressive but strict evaluation procedures. The U.K. has shown a great commitment, as it has spent £48 million on government grants channeled by U.K. Research and Innovation. The intellectual property creation in the field is also high and 66 DNA vaccine related patents are applied every year using the European Patent Office. Distribution is also vital in the region as the European Commission recorded the export of DNA vaccines worth 510 million Euros. This coupled with good academic-industry collaborations makes Europe a big contender to the DNA Vaccine Market.

The Asia Pacific region is quickly turning into a major growth market in regards to DNA vaccines with growing investments into health care and growing research capacities. India has shown high researcher activity with India Council of Medical Research has reported 38 registered clinical trials on DNA vaccine development. China has developed strong capabilities and recorded 41 targeted DNA vaccine-development laboratories within its borders by the China National Medical Products Administration. Japan plays a great role in the development of intellectual property, and 55 patents on DNA vaccine are issued by the Japan Patent Office per year. There are eight ongoing clinical trials of government-sponsored DNA vaccines in South Korea as announced by the Ministry of Food and Drug Safety. The capacity to manufacture in the region is also notable with the Chinese Ministry of Science and Technology citing 14 specialized production plants. The region is also significant in the global supply chain where 120 metric tons of DNA vaccine active pharmaceutical ingredients were exported per year as reported by General Administration of Customs, China. These changes are paired with an increase in R&D spending in the region, meaning that Asia Pacific is slated to gain a lot of market share in the immediate future.

Key Players Covered

The report includes the profiles of the following key players:

• INOVIO Pharmaceuticals (U.S.)
• Cadila Healthcare Limited (India)
• Genexine, Inc. (South Korea)
• Takis S.r.l. (Italy)
• VGXI (U.S.)
• Ichor Medical Systems (U.S.)

Key Industry Developments

• In June 2023, BioNTech announced a £1 billion investment to establish research centers in the U.K., focusing on personalized medicine and cancer vaccines.
• In May 2023, Baseimmune secured $14 million in funding to develop AI-driven vaccines targeting future pathogen mutations.